Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2019-11-18 Major Shareholding Noti…
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification
2019-11-18 English
10-Q
Interim / Quarterly Report Q3 2019
2019-11-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2019, by AnaptysBio, Inc. It announces the company's financial results for the nine months ended September 30, 2019, and includes press releases as exhibits. The document is a current report providing updates on financial results and clinical trial outcomes, typical of an earnings release or operational update. The length is 4571 characters, which is relatively short and the document references attached press releases for detailed financial results. The content is not a full annual or quarterly report but an announcement of financial results and other company news. Therefore, it fits best as an Earnings Release (ER) rather than a full Interim Report (IR) or Annual Report (10-K).
2019-11-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 30, 2019, by AnaptysBio, Inc. It announces the issuance of a press release with topline data from an interim analysis of a Phase 2 trial. The document includes a press release as an exhibit and explicitly states that the information is furnished and not filed, indicating it is an announcement rather than a full report. The content is typical of a Regulatory Filing (8-K) that provides current event updates rather than detailed financial statements or comprehensive reports. The document length is 3547 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-09-30 English
FORM 4 SUBMISSION
Director's Dealing
2019-09-26 English
FORM 3 SUBMISSION
Director's Dealing
2019-09-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.